Home » Topics » Disease categories and therapies » Urology

Urology
RSS

VS-505 effective and well tolerated hyperphosphatemia treatment for hemodialysis patients

Nov. 3, 2017

Cara Therapeutics doses first patient in study of CR-845

Oct. 26, 2017

FDA issues complete response letter for Xyosted

Oct. 23, 2017

Cara Therapeutics planning phase III pivotal program for CR-845

Oct. 17, 2017

Japan Tobacco enters licensing agreement for Rayaldee in Japan

Oct. 16, 2017

Vantia reports phase III topline data on fedovapagon for nocturia in men with BPH

Oct. 5, 2017

Soluble Nogo-B a potential treatment for diabetic glomerulopathy

Oct. 5, 2017

COLEC11, a possible therapeutic target for treating renal ischemia reperfusion injury

Oct. 2, 2017

First subject enrolled in phase III study of TRC-101 in chronic kidney disease

Sep. 29, 2017

The Brigham and Women's Hospital identifies SMOC2 inhibitors

Sep. 26, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...